In the United States, where the health system maintains a strong structural bias toward rapid access once the regulator approves a therapy, the 44-day outcome translates into virtually immediate insured access for more than 90 per cent of Americans through a mix of private and public coverage.
FDA approved new cancer therapy and delivers patient access in just 44 days
March 3, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Sanofi volunteers confront homelessness at Vinnies CEO Sleepout
June 19, 2026 - - Latest News -
Infectious diseases across the lifespan are a hidden burden beyond the acute episode
June 19, 2026 - - Latest News -
Gilead rushes remdesivir to Uganda to support Ebola response
June 19, 2026 - - Latest News -
Rhapsido approved in Australia as first oral targeted option for chronic spontaneous urticaria
June 18, 2026 - - Latest News -
Is China's international benchmarking a bigger short-term risk to medicines access?
June 18, 2026 - - Latest News -
Life sciences leaders brace for class action wave as dispute risks multiply
June 18, 2026 - - Latest News -
Australia's life sciences sector welcomes new CGT concession but urges RDTI fixes
June 18, 2026 - - Latest News

